Emergent Operations Ireland

Emergent Operations Ireland is an Irish operating entity within Emergent BioSolutions that appears to serve primarily as a legal, regulatory, and commercialization vehicle for certain Emergent products outside the United States, rather than as a standalone R&D biotech. Public regulatory records identify Emergent Operations Ireland Limited as the marketing authorization holder or sponsor for products including NARCAN Nasal Spray in Canada and orphan medicinal products such as raxibacumab and brincidofovir in the European Union. The company is associated with Emergent BioSolutions' broader portfolio of medical countermeasures and overdose-reversal products addressing public health threats such as opioid overdose, anthrax, orthopoxviruses, Ebola, and botulism. It is active and based in Dublin, Ireland, and should be understood as a subsidiary or affiliate-level legal entity embedded within Emergent BioSolutions' global specialty life sciences operations rather than an independent pipeline-stage biotechnology company.